method
studi
phase
openlabel
singlearm
doseescal
studi
done
walter
reed
armi
institut
research
clinic
trial
center
silver
spring
md
usa
enrol
healthi
adult
age
year
exclus
criteria
includ
previou
infect
treatment
mer
elig
particip
enrol
sequenti
use
doseescal
protocol
receiv
mg
mg
mg
administ
train
clinic
site
staff
via
singl
intramuscular
ml
inject
vaccin
baselin
week
week
follow
immedi
colocalis
intramuscular
electropor
enrol
higher
dose
group
occur
safeti
monitor
committe
review
data
follow
vaccin
first
five
particip
previou
lower
dose
group
primari
outcom
studi
safeti
assess
particip
receiv
least
one
studi
treatment
postdos
studi
data
avail
vaccin
period
followup
week
dose
safeti
measur
incid
advers
event
administr
site
reaction
pain
chang
safeti
laboratori
paramet
secondari
outcom
immunogen
trial
regist
clinicaltrialsgov
number
nct
complet
find
feb
juli
enrol
individu
alloc
mg
mg
mg
vaccineassoci
seriou
advers
event
report
common
advers
event
injectionsit
reaction
report
particip
overal
particip
report
least
one
solicit
advers
event
common
system
symptom
headach
five
mg
mg
mg
mg
selflimit
unsolicit
symptom
report
particip
deem
treatmentrel
common
unsolicit
advers
event
infect
occur
particip
six
deem
possibl
relat
studi
treatment
laboratori
abnorm
grade
higher
relat
studi
treatment
laboratori
abnorm
uncommon
except
increas
creatin
phosphokinas
particip
three
particip
mg
group
three
mg
group
seven
mg
group
increas
five
deem
possibl
relat
studi
treatment
one
mg
group
four
mg
group
seroconvers
measur
occur
particip
particip
two
three
vaccin
respect
neutralis
antibodi
detect
particip
tcell
respons
detect
particip
two
vaccin
particip
three
vaccin
differ
immun
respons
dose
group
week
week
vaccineinduc
humor
cellular
respons
detect
particip
respect
interpret
mer
coronaviru
vaccin
well
toler
vaccineassoci
seriou
advers
event
immun
respons
doseindepend
detect
particip
two
vaccin
durabl
year
followup
data
support
develop
vaccin
includ
addit
studi
test
efficaci
region
endem
mer
coronaviru
middl
east
respiratori
syndrom
mer
coronaviru
highli
fatal
caus
lower
respiratori
tract
infect
first
identifi
saudi
arabian
man
may
laboratoryconfirm
case
mer
associ
death
report
across
countri
report
infect
saudi
arabia
case
death
despit
low
transmiss
mer
coronaviru
human
threat
region
global
mer
epidem
substanti
exemplifi
continu
transmiss
outsid
middl
east
particularli
south
korean
outbreak
eman
singl
travel
result
case
death
correl
protect
mer
coronaviru
infect
diseas
definit
establish
anim
challeng
studi
shown
protect
sever
vaccin
howev
clearli
discrimin
bind
antibodi
neutralis
antibodi
tcell
respons
determin
protect
possibl
humor
cellular
immun
probabl
play
substanti
role
viral
clearanc
mitig
human
clinic
diseas
mer
coronaviru
infect
induc
neutralis
antibodi
persist
sever
year
passiv
transfer
either
monoclon
antibodi
polyclon
serum
sampl
abil
lower
viral
load
reduc
patholog
lung
sever
anim
model
howev
concentr
mer
coronaviru
neutralis
antibodi
alway
correl
viral
clearanc
surviv
diseas
sever
studi
saudi
arabia
show
tcell
respons
directli
correl
shorter
stay
hospit
intens
care
unit
lower
viral
load
respiratori
tract
given
uncertainti
defin
correl
protect
vaccin
candid
gener
humor
cellular
immun
respons
desir
preclin
experi
dna
vaccin
express
fulllength
mer
coronaviru
sglycoprotein
antigen
broadli
immunogen
mice
camel
nonhuman
primat
protect
nonhuman
primat
radiolog
histopatholog
evid
pneumonia
follow
mer
coronaviru
challeng
therefor
phase
studi
assess
safeti
immunogen
human
initi
phase
openlabel
singlearm
doseescal
studi
walter
reed
armi
institut
research
clinic
trial
center
silver
spring
md
usa
studi
approv
centr
institut
review
board
appendix
avail
onlin
contain
supplemetn
data
figur
tabl
clinic
studi
protocol
statist
analysi
plan
elig
particip
healthi
adult
age
year
abl
provid
consent
particip
sign
inform
consent
form
abl
will
compli
studi
procedur
women
childbear
potenti
agre
either
remain
sexual
abstin
use
medic
effect
contracept
oral
contracept
barrier
method
spermicid
partner
steril
enrol
month
follow
last
inject
partner
unabl
induc
pregnanc
sexual
activ
men
consid
sexual
fertil
must
agre
use
either
barrier
method
contracept
studi
agre
continu
use
least
month
follow
last
inject
partner
evid
studi
licens
vaccin
prevent
therapeut
treat
middl
east
respiratori
syndrom
mer
coronaviru
infect
mer
coronaviru
dna
vaccin
test
phase
clinic
trial
previous
report
immunogen
mice
camel
nonhuman
primat
protect
nonhuman
primat
clinic
diseas
challeng
model
pulmonari
infect
search
us
nation
librari
medicin
clinicaltrialsgov
european
union
clinic
trial
regist
databas
identifi
clinic
trial
mer
coronaviru
vaccin
use
term
mer
merscov
middl
east
respiratori
syndrom
vaccin
phase
clinic
trial
knowledg
data
human
clinic
trial
mer
coronaviru
vaccin
report
date
studi
show
mer
coronaviru
dna
vaccin
toler
immunogen
human
vaccin
induc
antibodybas
cellular
mer
coronavirusspecif
immun
respons
studi
also
compar
vaccinespecif
respons
individu
recov
natur
mer
coronaviru
infect
korean
outbreak
result
show
immun
respons
gener
vaccin
studi
particip
similar
convalesc
respons
natur
infect
unpredict
zoonot
transmiss
gener
decreas
number
case
mer
coronaviru
middl
east
make
futur
placebocontrol
trial
challeng
futur
test
ongo
phase
trial
south
korea
addit
randomis
clinic
trial
plan
test
vaccin
endem
region
vaccin
might
potenti
valu
respons
futur
mer
coronaviru
oubreak
global
public
health
commun
maintain
strong
interest
develop
vaccin
safe
effect
control
potenti
situat
mer
coronaviru
outbreak
see
onlin
appendix
perman
steril
unabl
becom
pregnant
normal
screen
electrocardiogram
ecg
screen
ecg
clinic
signific
find
screen
laboratori
find
must
within
normal
limit
grade
find
histori
clinic
signific
immunosuppress
autoimmun
diseas
current
within
previou
week
take
immunosuppress
drug
exclud
inhal
topic
skin
eye
dropcontain
corticosteroid
lowdos
methotrex
corticosteroid
dose
mgday
will
allow
storag
futur
use
sampl
mer
coronavirusrel
research
exclus
criteria
includ
previou
mer
coronaviru
infect
receipt
experiment
treatment
prevent
mer
serolog
evid
hiv
hepat
b
viru
hepat
c
viru
infect
administr
vaccin
within
week
first
dose
pregnanc
breastfeed
laboratori
screen
abnorm
grade
bodymass
index
administr
monoclon
polyclon
antibodi
product
within
week
first
dose
administr
blood
product
within
month
first
dose
baselin
evid
kidney
diseas
measur
creatinin
greater
mgdl
chronic
liver
diseas
cirrhosi
current
anticip
treatment
inhibitor
eg
infliximab
adalimumab
etanercept
previou
major
surgeri
radiat
therapi
within
week
group
assign
preexcit
syndrom
eg
wolffparkinsonwhit
syndrom
metal
implant
within
cm
plan
site
inject
presenc
keloid
scar
format
hypertroph
scar
clinic
signific
medic
condit
plan
site
inject
prison
particip
compulsorili
detain
involuntari
incarcer
treatment
either
physic
psychiatr
ill
activ
drug
alcohol
use
depend
opinion
investig
would
interfer
adher
studi
requir
assess
immunolog
endpoint
tattoo
cover
inject
site
area
presenc
cardiac
pacemak
automat
implant
cardiovert
defibril
investig
decis
relat
condit
might
interfer
studi
requir
full
protocol
appendix
p
particip
provid
written
inform
consent
enrol
separ
mer
coronaviru
naturalinfect
sampl
collect
studi
enrol
particip
seoul
nation
univers
hospit
snuh
seoul
south
korea
elig
particip
adult
previous
infect
mer
coronaviru
outbreak
south
korea
recov
ill
serum
collect
natur
infect
particip
time
acut
ill
diagnosi
particip
ask
return
collect
convalesc
phase
serum
peripher
blood
mononuclear
cell
studi
review
approv
snuh
institut
review
board
particip
provid
written
inform
consent
enrol
studi
vaccin
manufactur
vgxi
woodland
tx
usa
accord
good
manufactur
practic
contain
mgml
plasmid
steril
water
inject
plasmid
contain
gene
insert
design
optimis
fulllength
microconsensu
mer
coronaviru
sglycoprotein
gener
publicli
avail
clinic
sequenc
august
particip
enrol
sequenti
use
doseescal
protocol
receiv
one
three
dose
mg
mg
mg
per
vaccin
enrol
higher
dose
group
occur
safeti
monitor
committe
review
data
follow
vaccin
first
five
particip
previou
lower
dose
group
administ
particip
train
clinic
site
staff
singl
ml
intramuscular
deltoid
inject
follow
immedi
colocalis
intra
muscular
electropor
enhanc
cellular
entri
plasmid
dna
adapt
constant
current
electropor
devic
inovio
pharmaceut
plymouth
meet
pa
usa
describ
previous
site
inocul
threedos
seri
baselin
week
week
electropor
devic
appli
three
puls
interv
strength
current
voltag
v
per
puls
local
system
advers
event
record
studi
visit
grade
clinic
site
investig
addit
particip
ask
record
local
gener
symptom
week
follow
vaccin
memori
aid
review
studi
staff
follow
visit
screen
safeti
laboratori
assess
includ
complet
blood
count
compr
hensiv
metabol
panel
measur
alanin
amino
transferas
aspart
aminotransferas
creatin
phosphokinas
baselin
electrocardiogram
serum
sampl
collect
baselin
week
elisa
develop
inhous
assay
detail
appendix
p
done
detect
antibodi
bind
specif
subunit
amino
acid
mer
coronaviru
fulllength
sglycoprotein
fulllengthselisa
report
endpoint
titr
posit
cutoff
lowest
dilut
test
fulllength
elisa
serum
sampl
also
assess
abil
neutralis
mer
coronaviru
strain
infect
vero
cell
appendix
p
sampl
test
triplic
neutralis
antibodi
sampl
score
posit
two
three
replic
show
neutralis
activ
result
geometr
mean
titr
least
whole
blood
collect
process
peripher
blood
mononuclear
cell
isol
timepoint
collect
serum
sampl
except
peripher
blood
mononuclear
cell
collect
one
earli
timepoint
first
two
vaccin
week
tcell
respons
measur
enzymelink
immunospot
assay
incub
peripher
blood
mononuclear
cell
pool
overlap
peptid
peptid
per
pool
span
entir
mer
coronaviru
sglycoprotein
respons
report
spotform
unit
per
million
peripher
blood
mononuclear
cell
total
five
mer
peptid
pool
posit
respons
vaccin
defin
twice
studi
mean
baselin
least
spotform
unit
per
million
peripher
blood
mononuclear
cell
addit
multiparamet
intracellular
cytokin
stain
flow
cytometri
detect
cell
secret
tumour
necrosi
factor
tnf
follow
mer
coronaviru
speptid
stimul
done
evalu
sampl
baselin
week
appendix
p
serum
peripher
blood
mononuclear
cell
sampl
also
collect
individu
diagnos
mer
coronaviru
infect
korean
outbreak
convalesc
sampl
obtain
mean
month
sd
mer
diagnosi
acut
phase
serum
sampl
time
initi
admiss
hospit
collect
mean
day
diagnosi
day
symptom
onset
avail
small
volum
particip
sampl
analys
use
method
vaccin
sampl
test
serolog
immun
respons
individu
previous
report
follow
acut
infect
year
infect
primari
outcom
studi
safeti
measur
incid
advers
event
classifi
system
organ
class
prefer
term
sever
relationship
studi
treatment
schedul
administr
site
reaction
describ
frequenc
sever
grade
administr
site
pain
chang
safeti
laboratori
variabl
describ
frequenc
sever
grade
eg
liver
panel
test
vital
sign
secondari
outcom
studi
immunogen
assess
cellular
humor
respons
overal
dose
humor
immunogen
assess
qualit
quantit
elisa
bind
antibodi
titr
glycoprotein
subunit
fulllength
mer
coronaviru
glycoprotein
neutralis
antibodi
mer
coronaviru
strain
vero
cell
antigenspecif
cellular
immun
respons
mer
coronaviru
glycoprotein
assess
use
intracellular
cytokin
stain
assay
exploratori
outcom
comparison
bind
antibodi
mer
cov
neutralis
antibodi
titr
kinet
durabl
bind
antibodi
mer
coronaviru
neutralis
antibodi
titr
comparison
elispot
intracellular
cytokin
stain
respons
across
differ
vaccin
dose
kinet
durabl
elispot
express
full
length
mer
coronaviru
protein
peripher
blood
time
host
immunegenotyp
avail
epitop
map
tlymphocyt
respons
immunophenotyp
function
characteris
cellular
subset
interest
includ
natur
killer
cell
isol
express
characteris
monoclon
antibodi
mer
coronaviru
protein
assess
neutralis
nonneutralis
function
activ
studi
protocol
appendix
p
studi
design
exploratori
trial
defin
group
size
particip
per
dose
group
statist
power
measur
specif
outcom
safeti
analysi
popul
includ
particip
receiv
least
one
studi
treatment
postdos
safeti
data
avail
analys
treatment
receiv
perprotocol
analysi
popul
use
clinic
studi
report
primari
analysi
includ
particip
receiv
vaccin
dose
major
protocol
deviat
primari
endpoint
data
avail
ten
particip
exclud
perprotocol
analysi
inclus
modifi
intentiontotreat
itt
analysi
immunogen
compris
particip
receiv
least
one
dose
present
support
main
analysi
particip
popul
group
accord
origin
treatment
assign
fulllength
selisa
vero
neutralis
assay
result
report
geometr
mean
endpoint
titr
ci
dosegroup
timepoint
kruskalw
test
use
compar
valu
dose
timepoint
fisher
exact
test
use
compar
elisa
respons
rate
group
twosid
test
use
compar
mean
valu
group
intracellular
cytokin
stain
data
report
mean
frequenc
ci
mer
coronaviru
speptidestimul
cytokin
respons
cell
statist
signific
defin
twosid
pvalu
less
nomin
adjust
multipl
comparison
differ
acut
convalesc
sampl
natur
mer
coronaviru
infect
week
sampl
assess
oneway
anova
tukey
multipl
comparison
use
graphpad
prism
statist
softwar
analys
studi
regist
clinicaltrialsgov
number
nct
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
funder
full
access
data
studi
final
respons
decis
submit
public
feb
juli
sequenti
enrol
particip
assign
dose
group
figur
particip
demograph
characterist
tabl
reason
nonenrol
appendix
p
includ
individu
exclud
increas
creatin
phosphokinas
relat
vigor
exercis
regimen
mean
age
particip
year
sd
ten
particip
exclud
perprotocol
analysi
complet
studi
visit
figur
enrol
particip
complet
entir
threedos
vaccin
seri
figur
common
advers
event
injectionsit
reaction
report
particip
particip
report
least
one
solicit
advers
event
tabl
appendix
p
one
injectionsit
reaction
report
particip
dose
group
system
reaction
report
particip
mg
group
mg
group
mg
dose
group
common
solicit
system
advers
event
headach
follow
malais
fatigu
myalgia
solicit
advers
event
mild
group
one
particip
mg
dose
group
report
one
episod
sever
indur
follow
third
vaccin
resolv
within
h
one
seriou
advers
event
report
seconddegre
burn
report
occur
day
third
vaccin
particip
provid
inform
return
followup
princip
investig
deem
incid
unrel
studi
treatment
grade
higher
laboratori
abnorm
relat
studi
treatment
laboratori
abnorm
uncommon
except
increas
creatin
phosphokinas
occur
figur
trial
profil
ten
particip
complet
vaccin
seri
four
reloc
three
losttofollowup
two
becam
pregnant
studi
one
declin
final
vaccin
seroconvers
measur
occur
particip
week
second
vaccin
week
third
vaccin
differ
respons
rate
dose
group
week
onward
figur
appendix
p
seroconvers
also
note
mg
mg
mg
total
particip
two
vaccin
three
vaccin
elisa
seroreact
maintain
particip
studi
end
week
signific
differ
geometr
mean
endpoint
titr
dose
group
week
none
thereaft
figur
appendix
pp
similar
pattern
antibodi
respons
note
measur
fulllength
selisa
vaccin
particip
seroconvert
week
maintain
week
appendix
neutralis
antibodi
mer
coronaviru
infect
vero
cell
detect
particip
week
week
two
maintain
neutralis
activ
end
studi
overal
particip
detect
neutralis
antibodi
one
timepoint
studi
halfmaxim
neutralis
geometr
mean
endpoint
titr
peak
week
rang
figur
pearson
correl
neutralis
titr
fulllength
selisa
correl
neutralis
appendix
vaccin
induc
mer
coronaviru
sspecif
ifn
respons
particip
overal
tcell
respons
particip
week
second
vaccin
week
third
vaccin
particip
maintain
ifn
cellular
respons
end
studi
week
figur
vaccineinduc
humor
respons
detect
bind
antibodi
detect
particip
week
except
higher
respons
week
mg
group
versu
mg
group
week
mg
group
versu
mg
group
differ
tcell
respons
dose
group
appendix
p
respons
detect
five
peptid
pool
span
sglycoprotein
figur
tcell
respons
polyfunct
week
third
vaccin
appendix
p
dec
april
ten
adult
previous
infect
mer
enrol
separ
mer
coronaviru
naturalinfect
sampl
collect
studi
median
age
year
iqr
ten
particip
measur
bind
antibodi
acut
convalesc
sampl
appendix
p
fulllength
selisa
convalesc
sampl
appendix
p
neutralis
antibodi
persist
acut
convalesc
timepoint
nine
individu
although
low
three
appendix
p
compar
vaccineinduc
humor
cellular
respons
antibodi
titr
follow
natur
infect
significantli
higher
acut
phase
mersinfect
particip
differ
vaccin
neutralis
antibodi
convalesc
sampl
appendix
p
convalesc
tcell
respons
natur
infect
individu
broadbas
span
sglycoprotein
appendix
p
mean
total
spotform
unit
per
million
peripher
blood
mononuclear
cell
sd
versu
induc
week
although
differ
signific
studi
dna
vaccin
mer
coronaviru
well
toler
vaccineassoci
seriou
advers
event
report
common
intramuscular
inject
electropor
vaccin
immunogen
induc
seroconvers
tcell
respons
particip
bind
antibodi
seroconvers
tcell
respons
rapid
vaccin
induc
immun
respons
durabl
particip
maintain
detect
bind
antibodi
cellular
immun
respons
almost
year
last
vaccin
vaccineinduc
antibodi
cellular
immun
respons
similar
convalesc
phase
sampl
patient
recov
natur
mer
coronaviru
infect
final
vaccin
induc
polyfunct
tcell
respons
shown
correl
less
sever
diseas
lower
mer
coronaviru
shed
immun
respons
doseindepend
across
nearli
dose
rang
mg
mg
per
vaccin
suggest
dose
reduct
might
possibl
lower
dose
could
extend
vaccin
suppli
outbreak
situat
first
mer
coronaviru
vaccin
advanc
human
trial
among
vaccin
candid
develop
four
start
soon
start
phase
test
includ
measlesvector
chimpanze
adenovirusvector
modifi
vaccinia
ankaravector
vaccin
express
fulllength
sglycoprotein
dna
vaccin
viralvector
vaccin
use
recombin
technolog
allow
rapid
vaccin
design
respons
emerg
infecti
diseas
dna
vaccin
addit
advantag
rapid
manufactur
avoid
potenti
toxic
might
occur
live
viralvector
vaccin
underscor
potenti
rapid
deploy
dna
vaccin
advanc
clinic
within
month
preclin
vaccin
candid
select
phase
studi
design
measur
efficaci
would
requir
larger
randomis
studi
mer
coronavirusendem
region
studi
limit
firstinman
trial
primarili
assess
vaccin
safeti
studi
openlabel
singlearm
rather
randomis
placebocontrol
clinic
trial
absenc
placebo
group
could
introduc
bia
behalf
investig
particip
addit
studi
statist
power
measur
specif
outcom
limit
abil
detect
rare
event
conclus
phase
clinic
trial
show
toler
safeti
profil
robust
immunogen
mer
coronaviru
dna
vaccin
candid
vaccin
induc
similar
cellular
antibodi
respons
patient
recov
mer
coronaviru
natur
infect
ongo
phase
studi
south
korea
provid
addit
inform
immunogen
deliv
intraderm
inject
follow
electropor
abil
reduc
dna
vaccin
dose
addit
studi
requir
test
efficaci
region
endem
mer
advers
event
inject
site
reaction
consist
find
publish
clinic
trial
report
dna
vaccin
placebo
coadminist
mg
mg
mg
coronaviru
phase
trial
plan
assess
middl
east
south
korea
area
affect
mer
coronaviru
infect
gener
decreas
number
case
mer
middl
east
make
futur
placebocontrol
trial
challeng
howev
global
public
health
commun
maintain
interest
develop
vaccin
safe
effect
control
potenti
futur
outbreak
studi
design
